Back to Prevention

What Does the Research Say About Tenofovir Alafenamide?

What Does the Research Say About Tenofovir Alafenamide?
Bareback Guide 20 March 2026

Tenofovir alafenamide has been studied mainly in comparison with tenofovir disoproxil, since the clinical question has always been whether it delivers the same benefit with fewer harms. The answer is broadly yes, with one complication that emerged later.

What did the treatment trials show?

Registration studies compared single-tablet regimens containing alafenamide against otherwise identical regimens containing disoproxil. Viral suppression rates were comparable, meeting the criteria for non-inferiority, with no meaningful difference in how effectively the virus was controlled.

What did they show on kidney function?

Consistent improvement. Markers of kidney function and of tubular damage were better on alafenamide across studies, and people switching from the older form generally saw those markers improve. Serious kidney events were rare in both groups, and the difference is in the trend rather than in dramatic outcomes.

What about bone density?

Bone mineral density at the hip and spine declined less on alafenamide, and switching from the older form was associated with partial recovery. Whether that translates into fewer fractures over decades is not yet established, since the trials were not long enough or large enough to measure that directly.

What did the DISCOVER study test?

Alafenamide with emtricitabine against disoproxil with emtricitabine for PrEP, in men who have sex with men and transgender women. Both were highly effective with very few infections in either group. It found the newer combination non-inferior, with the expected differences in kidney and bone markers.

What was the limitation of that study?

It did not include cisgender women, so there is no comparable evidence for vaginal sex. That gap is why licensing for prevention has been narrower for alafenamide than for the older form, and why UK guidance has continued to use disoproxil as standard PrEP.

What emerged about weight?

Analyses across several studies found greater weight gain on alafenamide than on disoproxil, particularly in combination with integrase inhibitors. Interpreting this has proved difficult, and part of the picture appears to be that the older form suppresses weight and lipids rather than the newer form driving them up.

What does that mean in practice?

That the comparison is not simply newer and better. Someone with cardiovascular risk factors may be better served by the older form, and someone with reduced kidney function or bone disease by the newer one. It is a genuine trade-off rather than an upgrade.

What about lipids?

Cholesterol and triglycerides are consistently higher on alafenamide than on disoproxil in comparative studies. Again, much of this reflects the mild lipid-lowering effect of the older drug rather than an adverse effect of the newer one, and the clinical significance over decades is not settled.

What about hepatitis B?

Trials in chronic hepatitis B found comparable viral suppression to the older form with better kidney and bone markers, and it is an established option in that setting.

What questions remain open?

Whether the bone and kidney advantages translate into fewer clinical events over decades, and how much the weight and lipid differences matter for cardiovascular risk. Both are the subject of ongoing cohort work, and neither is settled.

How long has it been studied?

Around a decade in clinical use, with trial data preceding that. Substantial but shorter than the older tenofovir, which has over twenty years. For questions about effects over decades, the honest answer is that the data are still accumulating.

Does the evidence favour switching?

It depends what you are switching for. Kidney and bone markers improve; lipids and weight tend to move the other way. Someone with a specific reason to protect their kidneys benefits clearly, and someone doing well with no such reason may not.

Where can you read the evidence yourself?

NAM aidsmap summarises HIV research reliably and without overstatement, and the British HIV Association publishes the guidelines UK clinicians actually follow. Both are freely available and are considerably more useful than a general search, which tends to surface material from other countries with different practice.